Omega-3 fatty acids for depression in adults.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 34817851 · doi:10.1002/14651858.CD004692.pub5
What was done
A systematic review and meta-analysis of randomized controlled trials (searched to January 2021 across CENTRAL, MEDLINE, Embase, PsycINFO, trial registries, and grey literature) evaluating n-3 polyunsaturated fatty acids (n-3PUFAs) versus placebo, antidepressants, standard care, or wait-list control for adults with major depressive disorder (MDD). Primary outcomes were depressive symptom severity (continuous scale) and adverse events. Secondary outcomes included clinical response, remission, quality of life, and study non-completion. Evidence certainty was assessed using GRADE.
What was found
The review included 35 RCTs (34 vs. placebo, n = 1,924; 1 vs. antidepressant, n = 40). - Depressive symptoms vs. placebo: SMD -0.40 (95% CI -0.64 to -0.16; 33 studies, 1,848 participants; very low-certainty evidence), corresponding to ~2.5 points on the 17-item HDRS (below the minimal clinically important difference of 3.0 points). - Adverse events vs. placebo: OR 1.27 (95% CI 0.99 to 1.64; 24 studies, 1,503 participants; very low-certainty evidence). - Remission vs. placebo: OR 1.13 (95% CI 0.74 to 1.72; 8 studies, 609 participants; low-certainty evidence). - Response vs. placebo: OR 1.20 (95% CI 0.80 to 1.79; 17 studies, 794 participants; low-certainty evidence). - Quality of life vs. placebo: SMD -0.38 (95% CI -0.82 to 0.06; 12 studies, 476 participants; very low-certainty evidence). - Study non-completion vs. placebo: OR 0.92 (95% CI 0.70 to 1.22; 29 studies, 1,777 participants; very low-certainty evidence). - Versus antidepressants: 1 study (40 participants) found no difference in depressive symptoms (MD -0.70, 95% CI -5.88 to 4.48), response (OR 1.23, 95% CI 0.35 to 4.31), or non-completion (OR 1.00, 95% CI 0.21 to 4.71).
Why it matters
Omega-3 supplementation produces a small reduction in depressive symptoms compared to placebo that is unlikely to be clinically meaningful. There is currently insufficient high-certainty evidence to support omega-3 fatty acids as a treatment for major depressive disorder.
Limits
Evidence certainty across all outcomes was low to very low due to severe heterogeneity, imprecision, and risk of bias (including funnel plot asymmetry and sensitivity analyses indicating positive publication bias). The comparison against active antidepressant treatment relied on a single trial of only 40 participants.
Cited by
- context Omega-3 fatty acids are equally effective as antidepressants in head-to-head comparisons for depression.